
Masonic Cancer Center, University of Minnesota

Research Program: Transplant Biology & Therapy
Assistant Professor, Department of Pediatrics, Hematology-Oncology
verneris@umn.edu
612-626-2961 — office
Preferred method of contact: phone
Dr. Verneris' clinical profile
(University of Minnesota Physicians Web site)
Dr. Verneris is an assistant professor of pediatrics, Division of Hematology-Oncology, Blood and Marrow Transplantation, and the Cancer Center. His clinical interests include umbilical cord blood and/or bone marrow transplantation for acute leukemias, prevention of graft-versus-host disease and graft-versus-leukemia.
He received his medical degree in 1992 from the Dartmouth-Brown Program in Medicine (Hanover, New Hampshire and Providence, Rhode Island). He completed his pediatric internship and residency at Children's National Medical Center, Washington, D.C. His pediatric hematology/oncology fellowship was completed at Stanford University, Stanford, Calif., where he was a staff physician from 1998 to 2002, prior to joining the faculty at the University of Minnesota. He is board certified in pediatrics and pediatric hematology/oncology.
Dr. Verneris's research interests include immunology, transplantation biology and therapy, and translational research. Areas of specific interest include:
He serves on the University of Minnesota Institutional Biosafety Committee and the All-University Radiation Protection Advisory Committee. Dr. Verneris is a reviewer for multiple scientific journals. He has been the recipient of numerous awards and is currently recipient of the Alexander Charles Jundt Research Award. Dr. Verneris is principal investigator on a number of grants, including two from the National Institutes of Health (K08-HL004505 and P30CA077598-07, pilot 19) and the Children's Oncology Group. He has 32 peer-reviewed publications.
Wang H, Grzywacz B, Sukovich D, McCullar V, Lee AB, Blazar BR, Cornfield D, Miller JS, Verneris MR. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood. 2007 May 10; [Epub ahead of print]
Grzywacz B, Kataria N, Sikora M, Oostendorp RA, Dzierzak EA, Blazar BR, Miller JS, Verneris MR. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006 Aug 10
Kornacker M, Verneris MR, Kornacker B, Ganten TM, Schefford C, Negrin RS. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy. 2006;8:13-23.
Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, De For TE, Baker KS, Verneris MR. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant. 2006;37:175-181.
Verneris MR, Arshi A, Kornacker M, Edinger M and Negrin RS. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res. 2005;11:4561-4570.
Peters A, Manivel JC, Dolan M, Gulbahce EH, Baker KS, Verneris MR. Pulmonary cytolytic thrombi after allogeneic hematopoietic cell transplantation: a further histologic description. Biol Blood Marrow Transplant. 2005;11:484-485.
Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004 Apr 15;103(8):3065-72. Epub 2003 Nov 20.